DeepIntelligence Pharma Files IPO Prospectus: Pioneering End-to-End AI and Blockchain Platform for Drug Development

Artificial intelligence and blockchain are emerging technologies that have recently garnered significant attention. In the field of new drug development, these two technologies are poised to bring about a disruptive revolution in both productivity and production relations. As technological ceilings rise and more players enter the arena—particularly when seasoned teams from multinational pharmaceutical companies converge with top-tier internet AI teams—pharmaceutical R&D is expected to achieve a two-stage leap over the next three years, bypassing mere automation to directly realize intelligentization. The high barriers traditionally associated with new drug development are gradually being dismantled, unlocking immense potential for innovation and growth.

The AI Storm Arrives: Disruptive Revolution or Incremental Innovation? The drug development sector has long been characterized by high barriers to entry, high risks, and substantial capital requirements, yet it offers the potential for high returns. Under the guidance of emerging technologies, can global pharmaceutical companies leverage this wave of technological innovation to achieve a leap forward?

Deep Intelligenceis a company that utilizes the most advancedArtificial Intelligence and Blockchain TechnologyAn international startup empowering the entire lifecycle of new drug development, from R&D to post-launch. We are dedicated to building an end-to-end AI-driven drug discovery platform that empowers and accelerates any pharmaceutical company worldwide in efficiently and high-quality bringing drugs from the laboratory to the market. We are the industry’sDisruptive Innovators, since its establishment six months ago, it has successively launched 10 products and established use cases with the headquarters of multiple multinational pharmaceutical companies, as well as their Asia-Pacific and China divisions, along with leading domestic pharmaceutical enterprises. Deep Intelligence is continuously leveraging AI to integrate more segments of new drug R&D. We possess the capability for collaborative group operations, paving an innovative path rarely trodden by others.

As part of the DIA 2018 China Annual MeetingTop Diamond Sponsor, in a 100-square-meterNo.218At the custom-built booth, DeepIntellect looks forward to meeting you to touch the future. DeepIntellect will showcase what the landscape of new drug development will look like three years from now, when the entire R&D process is empowered by AI.Seeing is Believing. Product line managers and AI experts from DeepGlint are waiting for you at the custom-built booth, where multiple mystery gifts await and on-site signings come with discounts.

Furthermore, at the DIA Annual Meeting, which brings together numerous industry leaders, we will invite distinguished guests to participate in the Artificial Intelligence Subforum to share insights on the research and application of AI and blockchain in pharmaceutical transformation and drug development. Mr. Guan Zheng, Chief Scientific Officer of Depthwise Intelligence, will present the full process of model-based, AI-driven drug development.

Research and Application of Artificial Intelligence and Blockchain in Pharmaceutical Transformation and Drug Development

May 25, 2018 8:30–10:00

2nd Floor, Beijing International Convention Center, Conference Room 201AB

Li Xing

Founder & CEO of DeepGlint

The New Era's Curve: AI Technology Empowers Model-Based Drug Development

Guan Zheng

Chief Scientific Officer & Founding Partner of DeepBrain Chain

Opportunities and Challenges of Artificial Intelligence in Medical Image Analysis

Zhong Xin

Founder & CEO of Tuma Shenwei

Implementation of Blockchain Technology’s Business Model in the Healthcare Sector

Liu Zongyu

Dean, VCBeat Eggshell Institute

Website: www.deepintepharma.com

Email: contact@deepintepharma.com